STCube "BioUSA Highlights Immune Checkpoint Inhibitor New Drug Pipeline"

[Asia Economy Reporter Hyunseok Yoo] STCube, a bio company developing immuno-oncology drugs, announced on the 22nd that it participated in the world's largest bio industry exhibition, ‘BIO International Convention 2021 (hereinafter Bio USA),’ where it shared information about pipelines under research and development with global pharmaceutical companies and discussed collaboration on new drug development.

At ‘Bio USA,’ held until the 18th (local time in the U.S.), STCube introduced its immune checkpoint inhibitor candidate through online meetings conducted as part of the ‘Bio One-on-One Partnering’ program and negotiated joint development and technology licensing.

STCube discovered the immune checkpoint protein ‘BTN1A1’ for the first time in the world through its own screening program. The company completed the development of the new drug candidate antibody ‘hSTC810’ targeting ‘BTN1A1’ and plans to initiate full-scale global clinical trials starting in the second half of this year.

Prior to the global clinical trials of the ‘hSTC810’ antibody, STCube is conducting toxicity tests with Charles River Laboratories, a global contract research organization (CRO) based in the U.S. The antibody for clinical use is being smoothly produced through Samsung Biologics, a contract development and manufacturing organization (CDMO).

A company official stated, "We held online meetings with numerous global pharmaceutical companies at ‘Bio USA’ and agreed to hold additional meetings in the future," adding, "Many global pharmaceutical companies that participated in the meetings paid close attention to the preclinical results of our glyco-specific antibody and showed high expectations for the excellent preclinical results and global clinical trials of the innovative new drug ‘hSTC810.’"

He continued, "Along with the global Phase 1 clinical trials scheduled to begin in the second half of the year, we plan to explore various collaborations with global pharmaceutical companies."

This content was produced with the assistance of AI translation services.